| Literature DB >> 31481419 |
Mark Yarchoan1, Parul Agarwal2, Augusto Villanueva3, Shuyun Rao4, Laura A Dawson5, Josep M Llovet6,7,8, Richard S Finn9, John D Groopman10, Hashem B El-Serag11, Satdarshan P Monga12, Xin Wei Wang13, Michael Karin14, Robert E Schwartz15, Kenneth K Tanabe16, Lewis R Roberts17, Preethi H Gunaratne18, Allan Tsung19, Kimberly A Brown20, Theodore S Lawrence21, Riad Salem22, Amit G Singal23, Amy K Kim24, Atoosa Rabiee25, Linda Resar24, Yujin Hoshida23, Aiwu Ruth He26, Kalpana Ghoshal27, Patrick B Ryan28, Elizabeth M Jaffee1, Chandan Guha29, Lopa Mishra4,25, C Norman Coleman30, Mansoor M Ahmed31.
Abstract
Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally. The landscape of systemic therapy has recently changed, with six additional systemic agents either approved or awaiting approval for advanced stage HCC. While these agents have the potential to improve outcomes, a survival increase of 2-5 months remains poor and falls short of what has been achieved in many other solid tumor types. The roles of genomics, underlying cirrhosis, and optimal use of treatment strategies that include radiation, liver transplantation, and surgery remain unanswered. Here, we discuss new treatment opportunities, controversies, and future directions in managing HCC. ©2019 American Association for Cancer Research.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31481419 PMCID： PMC8330805 DOI： 10.1158/0008-5472.CAN-19-0803
Source DB: PubMed Journal: Cancer Res ISSN： 0008-5472 Impact factor: 12.701